Friday, January 7, 2011
Athersys Inc., of Cleveland, completed patient enrollment of the single-dose arm of a study involving administration of MultiStem to patients being treated for leukemia or other blood-borne cancers.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.